Pituitary response to early follicular-phase minidose gonadotropin releasing hormone agonist (GnRHa) therapy: Evidence for a second flare
- 1 May 1996
- journal article
- clinical trial
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 13 (5), 390-394
- https://doi.org/10.1007/bf02066170
Abstract
Purpose: Our purpose was to determine the pituitary response to minidose follicular-phase GnRHa and see if a second flare can be achieved. Method: A prospective, consecutive series of 12 couples with tubal-factor infertility underwent 14 cycles of minidose GnRHa. Women were given a 25- or 50-µg dose of leuprolide acetate (LA) on cycle days 2 and 5. On cycle days 3 and 4 no LA was given but 2 ampoules of pure follicle stimulating hormone (FSH) was administered. Beginning day 6, a combination of LA and FSH was administered. Results: Following a dose of only 25µg of LA on cycle day 2, mean FSH, LH, and E2 levels were significantly elevated over the baseline levels. Following no LA on cycle day 3 or 4, a repeat dose of 25µg LA caused a second flare of LH and E2 on cycle day 6. Of the 14 cycles, 6 were canceled because of poor stimulation. Two of the eight patients who underwent retrieval delivered a live birth. Conclusions: This is the first study to examine both the pituitary response and the recovery time from minidose follicular-phase GnRHa. An extremely small dose of LA is needed to cause a pituitary flare of gonadotropins. Following a flare from 25µg of LA on cycle day 2, the pituitary is able to recover and respond with a repeat flare on cycle day 5.Keywords
This publication has 27 references indexed in Scilit:
- Elevated luteinizing hormone on the day of human chorionic gonadotropin administration does not reduce cycle fecundity in a low-dose flare-up in vitro fertilization protocol**Supported in part by the Vicksburg Hospital Medical Foundation, Vicksburg, Mississippi.††Presented at the Conjoint Meeting of The American Fertility Society and the Canadian Fertility and Andrology Society, Montreal, Quebec, Canada, October 11 to 14, 1993.Fertility and Sterility, 1995
- Elevated serum progesterone levels on the day of human chorionic gonadotropin administration do not predict outcome in assisted reproduction cyclesFertility and Sterility, 1994
- Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levelsFertility and Sterility, 1994
- Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transferFertility and Sterility, 1993
- Serum Progesterone Levels Predict Success ofin VitroFertilization/Embryo Transfer in Patients Stimulated with Leuprolide Acetate and Human Menopausal Gonadotropins*Journal of Clinical Endocrinology & Metabolism, 1991
- In Vitro Fertilization in Unstimulated CyclesObstetrics & Gynecology, 1990
- Gonadotropin and Estradiol Levels During Ovarian Stimulation in Women Treated With Leuprolide AcetateObstetrics & Gynecology, 1989
- HETEROGENEITY OF THE POLYCYSTIC OVARY SYNDROME: CLINICAL, ENDOCRINE AND ULTRASOUND FEATURES IN 556 PATIENTSClinical Endocrinology, 1989
- Stimulation of Ovarian Follicular Maturation With Pure Follicle-Stimulating Hormone in Women with Gonadotropin DeficiencyJournal of Clinical Endocrinology & Metabolism, 1988
- Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phaseBJOG: An International Journal of Obstetrics and Gynaecology, 1985